In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with ¹⁸F-AV-133

Abstract

These findings indicate that the novel (18)F-labeled ligand (18)F-AV-133 can sensitively detect monoaminergic terminal reductions in PD patients. Studies with (18)F-AV-133 may allow the presymptomatic identification of individuals with disorders characterized by degeneration of dopaminergic nigrostriatal afferents.